Status:
UNKNOWN
Radiolabeled Molecules for Medullary Thyroid Cancer
Lead Sponsor:
Instituto Nacional de Cancer, Brazil
Conditions:
Medullary Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Medullary thyroid cancer is a neuroendocrine tumour. As so, it has somatostatin receptors in its membrane. Furthermore, very little is available to treat patients who have disease progression. The inv...
Detailed Description
Medullary thyroid carcinomas can also be located by scintigraphy with 111In-DTPA (diethylenetriamine pentaacetic acid) -octreotide. In some studies, there is a sensitivity for the detection of these t...
Eligibility Criteria
Inclusion
- Medullary Thyroid Cancer
- Doubling time calcitonin and CEA less than 6 months
- Measurable disease by cross- sectional imaging
- Irresectable tumors masses
- \> 18 years of age
Exclusion
- \< 18 years of age
- Disease that can be treated with new surgical procedure
- Stable disease
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2017
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01915485
Start Date
August 1 2013
End Date
February 1 2017
Last Update
September 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional do Cancer do Rio de Janeiro
Rio de Janeiro, Rio de Janeiro, Brazil